期刊
EPIGENOMICS
卷 8, 期 11, 页码 1519-1525出版社
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2016-0071
关键词
5-azacytidine; 5-aza-2 '-deoxycytidine; chondrosarcoma; DNA methylation; epigenetics
资金
- Gattegno fund
- Wechsler fund
- Sarcoma Foundation of America (SFA)
- National Cancer Institute (NCI)/NIH [CA 151452-01]
- Sarcoma SPORE/NIH
- Academic Enrichment Fund of MGH Orthopaedics
Chondrosarcoma (CS) is the second most common primary malignant bone tumor. Unlike other bone tumors, CS is highly resistant to conventional chemotherapy and radiotherapy, thus resulting in poor patient outcomes. There is an urgent need to establish alternative therapies for CS. However, the etiology and pathogenesis of CS still remain elusive. Recently, DNA methylation-associated epigenetic changes have been found to play a pivotal role in the initiation and development of human cancers, including CS, by regulating target gene expression in different cellular pathways. Elucidating the mechanisms of DNA methylation alteration may provide biomarkers for diagnosis and prognosis, as well as novel treatment options for CS. We have conducted a critical review to summarize the evidence regarding aberrant DNA methylation patterns as diagnostic biomarkers, predictors of progression and potential treatment strategies in CS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据